in 309 patients treated in japan since 2016. the average age was 49 the average days from gvhd onset to msc therapy was 27 days 24% had liver involvement 30% had 2 therapies prior to msc
improved response and survival rate was associated with patients that were under 18 treated within 14 days had non liver involvement had less than 3 or 4 prior therapies.
other therapies include ruxolinitnib, inolimomab, anithymocyte globulin. across the entire study group cells remain viable treatment option.
but when used on the right patients at the right time it is even better. the one size fits all approach being used in japan provides real world evidence for a more targeted application.
yet the market penetration remains high. see the chart for evaluation of % market share for drugs when others are first available.
MSB Price at posting:
68.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)